Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06358950 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

A Phase 2 study of Narcolepsy Type 1, sponsored by Alkermes.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target
20
Study locations

NCT06358950 is a Phase 2 study of Narcolepsy Type 1 that has completed, run by Alkermes. The registered enrollment target is 92 participants, below the 177-participant average among 6 other Narcolepsy Type 1 trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06358950, a Phase 2 study of Narcolepsy Type 1, has completed, sponsored by Alkermes.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo alone.

Conditions Studied

Narcolepsy Type 1

Interventions

  • DRUG Placebo
  • DRUG ALKS 2680

Study Locations (20)

California

  • Alkermes Investigational Site - Los Angeles
  • Alkermes Investigational Site - Redwood City
  • Alkermes Investigator Site - San Francisco
  • Alkermes Investigational Site - Santa Ana

Florida

  • Alkermes Investigational Site - Brandon
  • Alkermes Investigator Site - Brandon
  • Alkermes Investigational Site - Miami
  • Alkermes Investigator Site - Winter Park

Georgia

  • Alkermes Investigational Site - Atlanta
  • Alkermes Investigational Site - Macon
  • Alkermes Investigational Site - Stockbridge

Colorado

  • Alkermes Investigational Site - Aurora
  • Alkermes Investigational Site - Colorado Springs

Michigan

  • Alkermes Investigator Site - Lansing
  • Alkermes Investigator Site - Sterling Heights

North Carolina

  • Alkermes Investigational Site - Denver
  • Alkermes Investigational Site - Huntersville

Illinois

  • Alkermes Investigator Site - Peoria

Nebraska

  • Alkermes Investigator Site - Lincoln

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2024-03-28
Est. Completion 2025-07-31
Phase Phase 2

Sponsor

Alkermes

66 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06358950

The ClinicalTrials.gov registry entry for NCT06358950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 6 other Narcolepsy Type 1 trials with a reported enrollment target (48% lower). The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Narcolepsy Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06358950 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06358950 about?

NCT06358950 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)". The purpose of this research study is to assess the safety and efficacy of ALKS 2680 compared to placebo, including whether participants taking ALKS 2680 experience a greater decrease in sleepiness and a decrease in cataplexy ("sudden loss of muscle control"), compared to participants taking placebo...

What is the current status of trial NCT06358950?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2024-03-28. Estimated completion is 2025-07-31.

What conditions does trial NCT06358950 study?

This clinical trial studies the following conditions: Narcolepsy Type 1.

What interventions are being tested in trial NCT06358950?

The interventions under investigation include: Placebo (DRUG), ALKS 2680 (DRUG).

Who is sponsoring clinical trial NCT06358950?

This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06358950 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Narcolepsy Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Narcolepsy Type 1

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.